Department of Psychological and Brain Sciences, Indiana University, Bloomington.
Center for Health Statistics, University of Chicago, Chicago, Illinois.
JAMA Pediatr. 2018 May 1;172(5):423-430. doi: 10.1001/jamapediatrics.2017.5641.
Adults with mental health conditions are more likely than those without to receive long-term opioid therapy. Less is known about opioid therapy among adolescents, especially those with mental health conditions.
To examine associations between preexisting mental health conditions and treatments and initiation of any opioid and long-term opioid therapy among adolescents.
DESIGN, SETTING, AND PARTICIPANTS: A cohort of 1 224 520 incident opioid recipients without cancer diagnoses aged 14 to 18 years at first receipt was extracted from nationwide commercial health care claims data from January 1, 2003, to December 31, 2014. Analysis was conducted from August 19, 2016, to November 16, 2017. Associations between preexisting mental health conditions and treatments and any opioid receipt were examined by comparing recipients with nonrecipients matched on sex, calendar year and years of age of first enrollment, and months of enrollment (prior to the index month for recipients, ever for nonrecipients). Associations between preexisting mental health conditions and treatments and subsequent long-term opioid therapy were examined among recipients with at least 6 months' follow-up using Cox proportional hazards regressions adjusted for demographics.
Mental health condition diagnoses and treatments recorded in inpatient, outpatient, and filled-prescription claims prior to opioid receipt.
Opioid receipt, defined as any opioid analgesic prescription claim, and long-term opioid therapy, defined as more than 90 days' supply within a 6-month window having no gaps in supply of more than 32 days.
Of the 1 224 520 new opioid recipients included, the median age at first receipt was 17 years (interquartile range, 16-18 years), and 51.1% were female. Median follow-up after first receipt was 625 days (interquartile range, 255-1268 days). Adolescents with anxiety, mood, neurodevelopmental, sleep, and nonopioid substance use disorders and most mental health treatments were significantly more likely to receive any opioid (odds ratios from 1.13 [95% CI, 1.10-1.16] for nonopioid substance use disorders to 1.69 [95% CI, 1.58-1.81] for nonbenzodiazepine hypnotics). Among the 1 000 453 opioid recipients (81.7%) who had at least 6 months' follow-up, the cumulative incidence of long-term opioid therapy was 3.0 (95% CI, 2.8-3.1) per 1000 recipients within 3 years after first opioid receipt. All preexisting mental health conditions and treatments were strongly associated with higher rates of long-term opioid therapy (adjusted hazard ratios from 1.73 [95% CI 1.54-1.95] for attention-deficit/hyperactivity disorder to 8.90 [95% CI, 5.85-13.54] for opioid use disorder).
Commercially insured adolescents with many types of preexisting mental health conditions and treatments were modestly more likely to receive any opioid and were substantially more likely to subsequently transition to long-term opioid therapy relative to those without, although overall rates of long-term opioid therapy were low.
患有心理健康问题的成年人比没有心理健康问题的成年人更有可能接受长期阿片类药物治疗。关于青少年使用阿片类药物的情况,尤其是患有心理健康问题的青少年,了解较少。
研究在青少年中,与预先存在的心理健康状况和治疗相关的因素与任何阿片类药物和长期阿片类药物治疗的开始之间的关系。
设计、地点和参与者:从 2003 年 1 月 1 日至 2014 年 12 月 31 日,从全国商业医疗保健索赔数据中提取了 1224520 名年龄在 14 至 18 岁之间、首次接受阿片类药物治疗且没有癌症诊断的新阿片类药物接受者的队列。分析于 2016 年 8 月 19 日至 2017 年 11 月 16 日进行。通过比较在性别、日历年份和首次入组的年龄以及入组月份(对于接受者为索引月份之前,对于非接受者为始终)上与非接受者匹配的接受者和非接受者,检查预先存在的心理健康状况和治疗与任何阿片类药物接受之间的关系。在至少有 6 个月随访的接受者中,使用 Cox 比例风险回归分析调整人口统计学因素,检查预先存在的心理健康状况和治疗与随后的长期阿片类药物治疗之间的关系。
在接受阿片类药物之前的住院、门诊和配药索赔中记录的心理健康状况诊断和治疗。
阿片类药物接受,定义为任何阿片类药物镇痛处方申请;长期阿片类药物治疗,定义为在 6 个月的窗口内接受超过 90 天的供应,且供应无超过 32 天的中断。
在纳入的 1224520 名新阿片类药物接受者中,首次接受治疗的中位年龄为 17 岁(四分位距,16-18 岁),51.1%为女性。首次接受治疗后的中位随访时间为 625 天(四分位距,255-1268 天)。患有焦虑症、心境障碍、神经发育障碍、睡眠障碍和非阿片类物质使用障碍以及大多数精神健康治疗的青少年,更有可能接受任何阿片类药物(比值比从非阿片类物质使用障碍的 1.13 [95%CI,1.10-1.16]到非苯二氮䓬类催眠药的 1.69 [95%CI,1.58-1.81])。在至少有 6 个月随访的 1000453 名阿片类药物接受者(81.7%)中,在首次接受阿片类药物后的 3 年内,长期阿片类药物治疗的累积发生率为每 1000 名接受者 3.0(95%CI,2.8-3.1)。所有预先存在的心理健康状况和治疗均与长期阿片类药物治疗的更高发生率密切相关(调整后的危险比从注意力缺陷/多动障碍的 1.73 [95%CI 1.54-1.95]到阿片类药物使用障碍的 8.90 [95%CI,5.85-13.54])。
在商业保险的青少年中,许多预先存在的心理健康状况和治疗的患者,与没有心理健康问题的患者相比,接受任何阿片类药物的可能性略高,随后过渡到长期阿片类药物治疗的可能性也显著更高,尽管长期阿片类药物治疗的总体比率较低。